Advertisement

More articles from Cancer Biology and Signal Transduction

  • Targeting Androgen Receptor Interactions with Chromatin
    Kush Dalal, Meixia Che, Nanette S. Que, Aishwariya Sharma, Rendong Yang, Nada Lallous, Hendrik Borgmann, Deniz Ozistanbullu, Ronnie Tse, Fuqiang Ban, Huifang Li, Kevin J. Tam, Mani Roshan-Moniri, Eric LeBlanc, Martin E. Gleave, Daniel T. Gewirth, Scott M. Dehm, Artem Cherkasov, Paul S. Rennie
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2281-2291; DOI: 10.1158/1535-7163.MCT-17-0259
  • ABCB1 Confers Cross-Resistance to Cabazitaxel and Docetaxel
    Alan P. Lombard, Chengfei Liu, Cameron M. Armstrong, Vito Cucchiara, Xinwei Gu, Wei Lou, Christopher P. Evans, Allen C. Gao
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2257-2266; DOI: 10.1158/1535-7163.MCT-17-0179
  • CDK10 Inhibits Tumor Growth in Colorectal Cancer
    Louis-Bastien Weiswald, Mohammad R. Hasan, John C.T. Wong, Clarissa C. Pasiliao, Mahbuba Rahman, Jianhua Ren, Yaling Yin, Samuel Gusscott, Sophie Vacher, Andrew P. Weng, Hagen F. Kennecke, Ivan Bièche, David F. Schaeffer, Donald T. Yapp, Isabella T. Tai
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2292-2303; DOI: 10.1158/1535-7163.MCT-16-0666
  • IGF2 Overexpression Predicts IGF1R/INSR Inhibitor Response
    Michael P. Sanderson, Marco H. Hofmann, Pilar Garin-Chesa, Norbert Schweifer, Andreas Wernitznig, Stefan Fischer, Astrid Jeschko, Reiner Meyer, Jürgen Moll, Thomas Pecina, Heribert Arnhof, Ulrike Weyer-Czernilofsky, Stephan K. Zahn, Günther R. Adolf, Norbert Kraut
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2223-2233; DOI: 10.1158/1535-7163.MCT-17-0336
  • OPCML Sensitizes HER2+ Cancers to Anti-HER2/EGFR Therapy
    Elisa Zanini, Louay S. Louis, Jane Antony, Evdoxia Karali, Imoh S. Okon, Arthur B. McKie, Sebastian Vaughan, Mona El-Bahrawy, Justin Stebbing, Chiara Recchi, Hani Gabra
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2246-2256; DOI: 10.1158/1535-7163.MCT-17-0081
  • Ormeloxifene and Prostate Cancer
    Bilal Bin Hafeez, Aditya Ganju, Mohammed Sikander, Vivek K. Kashyap, Zubair Bin Hafeez, Neeraj Chauhan, Shabnam Malik, Andrew E. Massey, Manish K. Tripathi, Fathi T. Halaweish, Nadeem Zafar, Man M. Singh, Murali M. Yallapu, Subhash C. Chauhan, Meena Jaggi
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2267-2280; DOI: 10.1158/1535-7163.MCT-17-0157
  • Proinflammatory Cytokines and Drug Resistance
    Kazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Dennis Ruder, Carmen Behrens, Li Shen, Neda Kalhor, Juhee Song, J. Jack Lee, Jing Wang, Ximing Tang, Roy S. Herbst, Shinichi Toyooka, Luc Girard, John D. Minna, Jonathan M. Kurie, Ignacio I. Wistuba, Julie G. Izzo
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2234-2245; DOI: 10.1158/1535-7163.MCT-17-0148
  • Decitabine and the MUC1-C Inhibitor Synergize in CTCL
    Salvia Jain, Abigail Washington, Rebecca Karp Leaf, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Dina Stroopinsky, Athalia Pyzer, Leandra Cole, Myrna Nahas, Arie Apel, Jacalyn Rosenblatt, Jon Arnason, Donald Kufe, David Avigan
    Molecular Cancer Therapeutics Oct 2017, 16 (10) 2304-2314; DOI: 10.1158/1535-7163.MCT-17-0060
  • JNK Modulation of Chemotherapy Response
    Matthew Ashenden, Antoinette van Weverwijk, Nirupa Murugaesu, Antony Fearns, James Campbell, Qiong Gao, Marjan Iravani, Clare M. Isacke
    Molecular Cancer Therapeutics Sep 2017, 16 (9) 1967-1978; DOI: 10.1158/1535-7163.MCT-16-0731
  • Chemoprotection by mTORC1 Inhibitors in B-ALL
    Thanh-Trang T. Vo, J. Scott Lee, Duc Nguyen, Brandon Lui, William Pandori, Andrew Khaw, Sharmila Mallya, Mengrou Lu, Markus Müschen, Marina Konopleva, David A. Fruman
    Molecular Cancer Therapeutics Sep 2017, 16 (9) 1942-1953; DOI: 10.1158/1535-7163.MCT-17-0024

Pages